时间标签：数据日期 2026-10-29 · 生成时间 2026-10-31 05:30（Asia/Shanghai）｜ 档位：观察哨11 ｜ 窗口 T-2 ｜ 上游评级 C
这项研究想回答什么
亚麻醉剂量氯胺酮的神经保护是否依赖经典 BDNF–TrkB 通路？
方法与数据
大鼠进展性 6-OHDA 帕金森模型的行为学 + 半定量 Western（TH）+ SNc 多巴胺神经元无偏体视学 + BDNF/TrkB 原位杂交，并设氯胺酮合并 TrkB 拮抗剂 ANA-12 的额外队列。
核心结论
以下所有数字均可在官方 abstract 原文（见第 7 节）中逐字核对；上游未给出的定量一律写「未给出」，不估算、不换算。
- 一句话贡献：纹状体内注射 6-OHDA 前给予氯胺酮（20 mg/kg，腹腔注射）具神经保护作用，近乎完全阻止帕金森样运动缺损的发生，而此时纹状体酪氨酸羟化酶仅中等程度保留（约 50–60% 丢失）。
局限与未核验项
单一啮齿类模型与单一给药时点，摘要未给各组动物数与统计值 → 待补全文；黑质体视学各组无显著差异、Western 相对 TH 含量未显著升高，行为与组织学证据不一致，摘要在结论处被截断。
补全文时优先核：各组动物数、ANA-12 队列结果、体视学与 Western 的统计量、被截断的结论部分。
⚠️ 本页为摘要级解读：未取得 PDF 全文，上述所有结论均未核至 Results/Methods；效应量、样本量、统计方法与多重比较校正在多数条目中仍未知。
对本领域的价值
提示氯胺酮的获益未必走经典 BDNF-TrkB 通路，对重新理解神经保护机制有价值；与衰老关联薄弱，属长尾命中。
编辑研判
有意思的点在「不一致」：20 mg/kg 氯胺酮近乎完全阻止 6-OHDA 大鼠的帕金森样运动缺损，而纹状体 TH 仅中等保留（约 50–60% 丢失），黑质体视学各组无显著差异——行为与组织学证据不吻合，提示获益未必走经典 BDNF-TrkB 通路（作者另设了 TrkB 拮抗剂 ANA-12 队列）。对衰老关联薄弱，但「保护不等于保住细胞数」这个提醒有通用价值。摘要无动物数与统计值。
官方摘要原文（逐字，供回溯）
展开 api.biorxiv.org / api.medrxiv.org 返回的 abstract 原文
Treatment with low-dose ketamine is neuroprotective in rodent models of acute damage, while high doses of ketamine can be neurotoxic. Our group has previously shown that sub-anesthetic ketamine treatment leads to long-term reduction of L-DOPA-induced dyskinesia (LID) via brain-derived neurotrophic factor (BDNF)-signaling in a rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease (PD). In this report, we investigated if sub-anesthetic ketamine is also neuroprotective in a progressive 6-OHDA model of PD via neurotrophic action through the tropomyosin receptor kinase B (TrkB) receptor. We demonstrated that ketamine-treatment (20 mg/kg, i.p.) prior to striatal administration of the neurotoxin 6-OHDA is neuroprotective, providing near complete protection against development of parkinsonian motor deficits. This robust behavioral efficacy occurred in the presence of only modest preservation of tyrosine hydroxylase (TH) striatal levels (~50-60% loss). Interestingly, based on data from an additional cohort treated with ketamine and ANA-12 (TrkB antagonist) we found that the neuroprotective effects of ketamine are not mediated by TrkB receptors. Semi-quantitative western analysis showed that the relative tyrosine hydroxylase content in the striatum was not significantly increased in ketamine-treated rats compared to vehicle. Unbiased stereology of dopamine neurons in the substantia nigra pars compacta (SNc) revealed no significant differences between any of the groups. The role of BDNF was evaluated with in situ hybridization for RNA of BDNF and TrkB. While BDNF expression was not changed, co-administration of ketamine and ANA-12 led to a significant decrease in TrkB receptor expression compared to ketamine-only on the lesioned but not the intact hemisphere in the SNc. In conclusion, we show that ketamine at the low dose currently pursued for therapeutic benefit for LID led to robust behavioral motor improvement in this rodent PD degeneration model, yet these protective effects were not driven by neurotrophic BDNF-signaling, indicating complex mechanisms are underlying neuroprotective activities of low-dose ketamine.
本文为预印本，未经同行评审，结论可能在正式发表时变更。生成任务 12819187（预印本全文级解读）· 上游 12784209（预印本速递）。
C 级证据分级：C 级（预印本，未经同行评审；本页为摘要级，未核至全文）
本文为预印本，未经同行评审；且本页为「摘要级」——未取得 PDF 全文（源站封锁），全部结论只依据官方 API 摘要原文。效应量、样本量、统计方法与多重比较校正在多数条目中仍未知，摘要未给出之处一律写「未给出」/「待补全文」，未做任何数值推算补全。
关于本文的文献来源：本站依据元层《预印本全文级解读_2026-10-31》（上游《预印本速递_2026-10-31》）撰写，附官方 abstract 原文供逐字回溯。